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doi:10.1016/j.kjms.2011.10.014Abstract This study investigated the clinical pathologic character of malignant gastrointes-
tinal stromal tumors (MGIST), their treatment with surgery, and evaluated the efficacy of
imatinib postoperation. A total of 68 MGIST patients were enrolled. Of these, 27 patients under-
went imatinib auxiliary therapy (treatment group) and 41 underwent imatinib therapy (control
group). The therapeutic effects on the two groups were compared using c2 test analysis after
follow-up of two years. The expressions of CD117, CD34, S100, Vimentin, and alpha smooth-
muscle actin (SMA) were detected by immunohistochemistry methods. Of the 68 cases, 28
showed potential MGIST, whereas 40 had MGIST. Haemorrhagia or necrosis, abundant cell, mani-
fest heteromorphism, and caryocinesia were observed in varying degrees. The positive rates of
CD117, CD34, Vimentin, S100, and SMA were 89.7% (61/62), 88.2% (60/62), 73.5% (50/62),
41.1% (28/62) and 25.0% (17/62), respectively. The recurrence rate in the treatment
group was significantly lower than that in the control group (p < 0.01). We concluded that
CD117 and CD34 may be the most valuable markers in the diagnosis of MGIST, and the diagnosis
of MGIST depends on the pathology. Surgery is a far better approach in the treatment of such
patients, and imatinib is themore efficient target drug in preventing recurrence andmetastasis.
Copyright ª 2012, Elsevier Taiwan LLC. All rights reserved.of General Surgery, The First
iated Hospital of Guangzhou
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Gastrointestinal stromal tumors (GIST) are mesenchymal
tumors occurring anywhere along the gastrointestinal tract
and are believed to originate from the interstitial cells of
Cajal. They commonly grow in the stomach or small intes-
tines [1,2]. These lesions have been classified as leiomyo-
mas or leiomyosarcomas because they possess smooth
muscle features under light microscopy.ed.
Character of MGIST and imatinib auxiliary therapy 213Malignant GIST (MGIST) comprises rare mesenchymal
tumors originating in the wall of the GI tract. The term
“GIST” was first introduced by Mazur and Clark in 1983 [1].
At present, only a few cases of MGIST have been reported
[2]. In the present study, 68 cases of MGIST were gathered
and analyzed. The clinical effects of imatinib mesylate
were observed and assessed as well.
Patients and methods
Patients
A total of 68 patients with MGISTwere diagnosed in the First
People’s Municipal Hospital of Guangzhou, Guangdong
Provincial People’s Hospital and the First Affiliated Hospital
of Guangzhou Medical College from March 1994 to March
2010. The current study was conducted in accordance with
the Declaration of Helsinki and was approved by the Ethics
Committee of First People’s Hospital of Guangzhou. Written
consent was obtained from all participating patients. The
diagnoses of all the caseswere pathologically defined. Of the
68 patients, 31 weremale and 37 female with an average age
of 55.3 years (from 32 to 73). Tumor sites included gastric
cardia (32 cases, 47.1%), small intestine (20 cases, 29.4%),
colon or rectum (7 cases, 10.3%), omentum (5 cases, 7.3%),
and mesenterium (4 cases, 5.9%). Symptoms that occurred
since admission into the study lasted from 3 days to 2 years.
Of these, 10 patients were diagnosed with symptoms for less
than 1month, 40 patients for a period of 1e6months, and 18
patients were diagnosed with symptoms for a period greater
than or equal to 6 months. The primary clinical symptoms
were abdominal pain (36, 53.3%), abdominal mass (11,
16.7%), pale appearance (22, 16.7%), melena (17, 26.1%),
abdominal distension (13, 19.1 %), weakness (7, 10.2 %),
eating difficulty (7, 10.2 %), sickness and vomiting (7, 10.2 %),
anorexia (5, 7.4 %), constipation (5, 7.4 %), diarrhea (3, 4.6
%), and ascites (3, 4.6 %).
Identification of MGIST
According to methods described by Miettinen et al. [3], GIST
are divided into benign stromal tumor (no malignant indi-
cator), potential malignant stromal tumor (one of any
potential malignant indicators), and definite malignant
stromal tumor (one of any definite malignant indicators or at
least two potential malignant indicators). The definite
malignant indicators are the distantmetastasis (identified by
pathology) and adjacent organ invasion. The potential
malignant indicators are as follows: (1) tumor diameter
greater than 5.5 cm; (2)mitoses greater than 5/50HPF or any
intestinal stromal tumor where mitosis occurs; (3) evident
necrosis of the tumor; (4) atypical nuclei; (5) heavy cell
density; (6) mucosa lamina propria and blood vessel invasion
that canbeobservedundermicroscope;and (7) anyepithelial
stromal tumors showing acinar or cellular sphere structure.
Immunohistochemistry
Paraffin wax-embedded sections were stained with hema-
toxylin and eosin. Immunohistochemical analysis wasconducted using the EnVision (DAKO, Glostrup, Denmark)
method. The antibodies used were CD117, CD34, Vimentin,
S100, and alpha smooth-muscle actin (SMA) (Zeta). For
antigen retrieval, slides were boiled with citrate buffer
(0.01 mol/L, pH 6.0) under high pressure for all the
antigens.
Treatment
All 68 patients with MGIST underwent different surgical
procedures, as follows: 30 cases of partial gastrectomy, two
cases of total gastrectomy, 20 cases of partial enterectomy,
seven cases of partial colectomy, five cases of omentum
resection, and four cases of partial mesenterectomy. All
patients underwent radical resection and had no residual
tumors.
The patients were randomly divided into two groups: 27
underwent the imatinib auxiliary therapy (treatment group)
and 41 patients underwent surgery without imatinib
therapy (control group).
Statistical analysis
The analyses presented in the current paper are explor-
ative. Differences in the treatment procedures or the use of
cytostatic drugs in different subgroups were evaluated by
means of a two-sided Chi-square test. A p value of less than
0.05 was considered statistically significant.
Results
Frequency and clinical features
Of the 68 patients, 28 cases were diagnosed with potential
MGIST with tumor diameters ranging from 3.2 cm to 7.2 cm
(mean of 5.3 cm). The cut surfaces were hoar or grayish
yellow, and the tumors were solid or hemorrhaging,
showing cystic changes. The other 40 cases were diagnosed
with MGIST with tumor diameters ranging from 3.0 cm to
25.0 cm (mean of 9.2 cm). The cut surfaces were fine-
textured, fish-like, and possessed an abundance of cells.
Some lesions were invaded or migrated locally (22 cases
invaded adjacent organs, 4 cases migrated into the liver, 14
cases showed no invasion or metastasis). Atypical mitoses
were significant. Hemorrhage and necrosis were also
observed (Fig. 1).
Immunohistochemical analysis
Of the 68 patients with MGIST, 61 cases were positive for
CD117 (89.7%), 60 cases expressed CD34 protein (88.2%),
and 50 cases were positive for Vimentin (73.5%). In addi-
tion, 28 cases were positive for S100 (41.1%), and only 17
cases expressed SMA protein (25.0%).
Treatment and follow-up
All thepatients receivedprimary tumor resection, andnoone
died immediately after surgery. The follow-up periods
ranged from 3 months to 5 years, and 17 of the patients died
Figure 1. The morphological characteristics of metastatic MGIST cells. (A) nuclear fission ; (B) cell atypia; (C) hemorrhagic
necrotics.
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recurrence, 33 were in the control group, together with 6
from the treatment group (x2Z 22.3, p< 0.05). The data are
shown in Table 1.
Discussion
According to the new histological classification of tumors,
mesenchymal tumor originates from muscles of nervous
type. Some stromal tumors may have been diagnosed with
leiomyoma of stomach [4]. Stromal tumors can be classifiedTable 1 Comparison of clinical data between control and
treatment groups (c2 test).
Group Control
(n Z 41)
Treatment
(n Z 27)
p
Gender
male 19 12 >0.05
female 22 15
Age (y) 47.3  14.15 49.87  15.37 >0.05
Tumor position
stomach 21 11 >0.05
small intestine 11 9
colorectal 4 3
omentum 3 2
mesenterium 2 2
Tumor malignant degree
potential MGIST 19 9 <0.05
MGIST 22 18 <0.05
Rate of follow-up 100% 100%
metastasis and
recurrence
within 5 years
33 6 <0.01
death 14 3 <0.05
MGIST Z malignant gastrointestinal stromal tumor.into smooth muscle, nerve tissue, as well as biphasic
differentiating and undifferentiating type. GIST was named
from pathology or molecular pathology, whereas MGIST
possessed the characters of c-kit genetic mutation and
activation.
CD117 and CD34 are highly expressed in MGIST, whereas
S100 and SMA are relatively lower. The immunohistochem-
istry results showed that CD117 and CD34 had positive rates
of 89.7% and 88.2%, respectively, consistent with previous
reports [5,6].
All symptoms of MGIST patients are generally nonspe-
cific. The main pathological evidence comprises large
tumor volume, invasive growth, and more mitoses (over 5/
50 HPF). Cassier [7] et al. reported that the prognosis of
MGIST is poor, and the median survival period is 5 years. In
the current work, a total of 35 out of 50 cases of MGIST
located in the small intestine received complete resection
but only 43% of the complete resection group suffered local
recurrence. In addition, 57% suffered distant metastasis
within 2 years after surgery with a 5-year survival rate of
43%. The 5-year survival rate of the incomplete resection
group was barely 7%. Finally, 34 patients died of tumor
recurrence [8].
At present, imatinib, a molecular targeting drug aiming
at c-kit gene, has shown advantages in the treatment of
MGIST [9]. Many known diseases are attributed to the
aberration of the signal transduction pathways in cells,
especially protein tyrosine kinase (PTK) P. Over activation
of PTK occurs in some malignant tumors and hyperplastic
benign tumors, and the inhibition of PTK activity can cure
hyperplastic diseases. Imatinib is a kind of PTK inhibitor
that can suppress c-kit gene of the platelet-derived growth
factor receptor and stem cell factor receptor, inhibiting the
biochemical reactions conducted by those two receptors
without affecting the signal transmissions conducted by
other simulating factors, such as epidermal growth factor
and insulin [10].
There were 17 cases of death in the present study,
including 14 from the control group and three from the
treatment group. Pierie et al. [11] divided 125 cases of GIST
Character of MGIST and imatinib auxiliary therapy 215into muscle-originated, nerve-originated, c-kit negative,
and c-kit positive cases. The tumors of c-kit positive are
bigger, more invasive, and result in more necrosis and
hemorrhage compared with the other groups. The survival
periods and qualities of this group are also poorer. All 68
cases in the present study were treated with primary tumor
resection and followed up for 3 months to 2 years. In all, 33
patients from the control group and six cases from the
treatment group suffered metastasis or recurrence, sug-
gesting that surgery alone might lead to an unsatisfactory
long-term prognosis [12,13].
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